Astria Therapeutics Inc
ATXS7.480USD
+0.090+1.22%
終値 09/18, 16:00（ET）15分遅れの株価
422.13M時価総額
損失額直近12ヶ月PER
詳細情報 Astria Therapeutics Inc 企業名
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
企業情報
企業コードATXS
会社名Astria Therapeutics Inc
上場日Jun 25, 2015
最高経営責任者「CEO」Dr. Jill C. Milne, Ph.D.
従業員数78
証券種類Ordinary Share
決算期末Jun 25
本社所在地22 Boston Wharf Road
都市BOSTON
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号02210
電話番号16173491971
ウェブサイトhttps://astriatx.com/
企業コードATXS
上場日Jun 25, 2015
最高経営責任者「CEO」Dr. Jill C. Milne, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Aug 16
更新時刻: Sat, Aug 16
株主統計
種類
株主統計
株主統計
比率
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Fairmount Funds Management LLC
6.30%
他の
60.44%
株主統計
株主統計
比率
Perceptive Advisors LLC
11.49%
Vestal Point Capital, LP
8.01%
Forbion Capital Partners
7.28%
Fidelity Management & Research Company LLC
6.48%
Fairmount Funds Management LLC
6.30%
他の
60.44%
種類
株主統計
比率
Investment Advisor
31.25%
Hedge Fund
22.38%
Investment Advisor/Hedge Fund
17.09%
Venture Capital
15.69%
Private Equity
11.49%
Research Firm
4.23%
Individual Investor
0.49%
Pension Fund
0.17%
Bank and Trust
0.09%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
263
60.10M
106.50%
-10.94M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
2023Q1
166
24.59M
91.65%
-670.60K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Perceptive Advisors LLC
6.49M
11.49%
--
--
Mar 31, 2025
Vestal Point Capital, LP
4.18M
7.41%
--
--
Mar 31, 2025
Forbion Capital Partners
3.82M
6.77%
+950.00K
+33.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
8.52%
-846.00K
-14.97%
Mar 31, 2025
Fairmount Funds Management LLC
3.55M
6.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
6.03%
-66.23K
-1.91%
Mar 31, 2025
Millennium Management LLC
2.94M
5.21%
+1.30M
+79.78%
Jun 13, 2025
Fidelity Institutional Asset Management
2.13M
3.78%
-40.96K
-1.89%
Mar 31, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.64M
4.68%
-29.10K
-1.09%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Sep 6
更新時刻: Sat, Sep 6
銘柄名
比率
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Avantis US Equity ETF
0%
iShares Russell 2000 ETF
0%
iShares Biotechnology ETF
0%
Schwab U.S. Broad Market ETF
0%
詳細を見る
ProShares Ultra Nasdaq Biotechnology
比率0.04%
Invesco Nasdaq Biotechnology ETF
比率0.04%
ProShares Hedge Replication ETF
比率0.01%
Proshares Ultra Russell 2000
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0%
Avantis US Equity ETF
比率0%
iShares Russell 2000 ETF
比率0%
iShares Biotechnology ETF
比率0%
Schwab U.S. Broad Market ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
日付
種類
比率
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
Aug 19, 2021
Merger
6→1
